Clinical Data Pepaxti study supports use in wider myeloma population PharmaTimesPhase 2 bridge data show consistent outcomes in patients with impaired kidney functionOncologyRead full story pharminent May 20, 2026 (Last updated: May 21, 2026) PharmaTimes Phase 2 bridge data show consistent outcomes in patients with impaired kidney function Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Beam one-ups Wave as both show promise of genetic editing for AATDNext: Pazdur declines to announce candidacy for vacated FDA commissioner role Related Stories Clinical Data Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test pharminent June 11, 2026 Clinical Data ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data pharminent June 9, 2026 Clinical Data ADA: AZ reveals oral GLP-1 data in obesity, diabetes pharminent June 9, 2026
